The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by BTIG on January 28, 2025. The analyst firm set a price target for $41.00 expecting ARCT to rise to within 12 months (a possible 141.60% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Arcturus Therapeutics (NASDAQ:ARCT) was provided by BTIG, and Arcturus Therapeutics initiated their buy rating.

The last upgrade for Arcturus Therapeutics Holdings Inc happened on May 11, 2023 when HC Wainwright & Co. raised their price target to $51. HC Wainwright & Co. previously had a neutral for Arcturus Therapeutics Holdings Inc.

The last downgrade for Arcturus Therapeutics Holdings Inc happened on November 10, 2022 when Baird changed their price target from N/A to $18 for Arcturus Therapeutics Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcturus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcturus Therapeutics was filed on January 28, 2025 so you should expect the next rating to be made available sometime around January 28, 2026.

While ratings are subjective and will change, the latest Arcturus Therapeutics (ARCT) rating was a initiated with a price target of $0.00 to $41.00. The current price Arcturus Therapeutics (ARCT) is trading at is $16.97, which is within the analyst’s predicted range.